These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33740890)

  • 1. Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies.
    Zhang W; Zhang Z; Krushkal J; Liu A
    BMC Med Res Methodol; 2021 Mar; 21(1):55. PubMed ID: 33740890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid pooled-unpooled design for cost-efficient measurement of biomarkers.
    Schisterman EF; Vexler A; Mumford SL; Perkins NJ
    Stat Med; 2010 Feb; 29(5):597-613. PubMed ID: 20049693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Logistic regression analysis of biomarker data subject to pooling and dichotomization.
    Zhang Z; Liu A; Lyles RH; Mukherjee B
    Stat Med; 2012 Sep; 31(22):2473-84. PubMed ID: 21953741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goodness-of-fit two-phase sampling designs for time-to-event outcomes: a simulation study based on New York University Women's Health Study for breast cancer.
    Lee M; Chen J; Zeleniuch-Jacquotte A; Liu M
    BMC Med Res Methodol; 2023 May; 23(1):119. PubMed ID: 37208600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power estimation in biomarker studies where events are already observed.
    Polley MC
    Clin Trials; 2017 Dec; 14(6):621-628. PubMed ID: 28776405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of archived specimens in evaluation of prognostic and predictive biomarkers.
    Simon RM; Paik S; Hayes DF
    J Natl Cancer Inst; 2009 Nov; 101(21):1446-52. PubMed ID: 19815849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS.
    Zheng Y; Brown M; Lok A; Cai T
    Ann Appl Stat; 2017 Jun; 11(2):638-654. PubMed ID: 28943991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive response-dependent two-phase designs: Some results on robustness and efficiency.
    Yang C; Diao L; Cook RJ
    Stat Med; 2022 Sep; 41(22):4403-4425. PubMed ID: 35799345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly efficient design strategy for regression with outcome pooling.
    Mitchell EM; Lyles RH; Manatunga AK; Perkins NJ; Schisterman EF
    Stat Med; 2014 Dec; 33(28):5028-40. PubMed ID: 25220822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust risk prediction with biomarkers under two-phase stratified cohort design.
    Payne R; Yang M; Zheng Y; Jensen MK; Cai T
    Biometrics; 2016 Dec; 72(4):1037-1045. PubMed ID: 27037494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient design and analysis of biospecimens with measurements subject to detection limit.
    Vexler A; Liu A; Schisterman EF
    Biom J; 2006 Aug; 48(5):780-91. PubMed ID: 17094343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sampling strategies to evaluate the prognostic value of a new biomarker on a time-to-event end-point.
    Graziano F; Valsecchi MG; Rebora P
    BMC Med Res Methodol; 2021 Apr; 21(1):93. PubMed ID: 33941092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficient case-control cluster sampling designs for population-based epidemiological studies.
    Ly T; Cockburn M; Langholz B
    Spat Spatiotemporal Epidemiol; 2018 Aug; 26():95-105. PubMed ID: 30390934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-phase stratified sampling and analysis for predicting binary outcomes.
    Cao Y; Haneuse S; Zheng Y; Chen J
    Biostatistics; 2023 Jul; 24(3):585-602. PubMed ID: 34923588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating longitudinal markers under two-phase study designs.
    Maziarz M; Cai T; Qi L; Lok AS; Zheng Y
    Biostatistics; 2019 Jul; 20(3):485-498. PubMed ID: 29912281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.